Compare SNY & IBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNY | IBN |
|---|---|---|
| Founded | 1994 | 1955 |
| Country | France | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4B | 108.2B |
| IPO Year | N/A | 1999 |
| Metric | SNY | IBN |
|---|---|---|
| Price | $48.33 | $29.64 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $61.50 | N/A |
| AVG Volume (30 Days) | 2.8M | ★ 4.3M |
| Earning Date | 01-29-2026 | 01-26-2026 |
| Dividend Yield | ★ 3.37% | 0.71% |
| EPS Growth | ★ 105.93 | 11.76 |
| EPS | ★ 8.67 | 0.83 |
| Revenue | ★ $53,890,648,839.00 | $21,493,768,246.00 |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $6.47 | $13.50 |
| P/E Ratio | ★ $5.47 | $17.91 |
| Revenue Growth | N/A | ★ 16.53 |
| 52 Week Low | $44.62 | $27.42 |
| 52 Week High | $60.12 | $34.57 |
| Indicator | SNY | IBN |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 31.33 |
| Support Level | $46.97 | $30.12 |
| Resistance Level | $49.24 | $30.37 |
| Average True Range (ATR) | 0.68 | 0.32 |
| MACD | -0.15 | -0.09 |
| Stochastic Oscillator | 36.99 | 3.50 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
ICICI Bank Ltd provides banking services. The company's operating segments include Retail Banking; Wholesale Banking; Treasury, Life insurance, Other Banking Business, and Others. The company generates maximum revenue from the Retail Banking segment which includes exposures of the Bank, which satisfy the four qualifying criteria of a regulatory retail portfolio as stipulated by RBI guidelines on the Basel III framework as well as includes income from credit cards, debit cards, third party product distribution, and the associated costs. Geographical segments include Domestic operations and Foreign operations. The company generates the majority of its revenue from the domestic operations.